GlaxoSmithKline joins Sosei's who's-who list of clients with global licensing pact for IBD small molecules

Kyle Blankenship

Big drugmakers are on the hunt for novel therapeutics in a range of ultra-competitive therapeutic areas. Japan’s Sosei Heptares has emerged in recent years as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

GlaxoSmithKline joins Sosei's who's-who list of clients with global licensing pact for IBD small molecules

Kyle Blankenship

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Glax­o­SmithK­line joins So­sei's who's-who list of clients with glob­al li­cens­ing pact for IBD small mol­e­cules

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

GlaxoSmithKline joins Sosei's who's-who list of clients with global licensing pact for IBD small molecules